AMG 701 诱导多发性骨髓瘤细胞毒性并清除食蟹猴浆细胞
本研究评估半衰期延长的抗 BCMA BiTE 分子 AMG 701 的体外和体内活性。体外平均半数有效浓度为 18.8 ± 14.8 pM,小鼠模型中所有测试剂量均完全抑制肿瘤形成(P < .001)。食蟹猴中浆细胞特异性基因清除达血液 93%、骨髓 85%,支持临床开发。
要点
- 小鼠模型中所有测试剂量完全抑制肿瘤形成(P < .001),并延长原位 MM 模型生存(P ≤ .01)。
- 食蟹猴中浆细胞特异性基因清除达血液 93%、骨髓 85%。
核心结论
- AMG 701 在体外和动物模型中显示抗多发性骨髓瘤活性并清除食蟹猴浆细胞,支持临床开发。
研究设计与样本
- 体外细胞实验、皮下小鼠异种移植模型、原位 MM 模型及食蟹猴体内评估。
- 食蟹猴中采用定量微滴式数字 PCR 检测浆细胞特异性基因,灵敏度为 0.1%。
主要发现
- AMG 701 体外诱导针对表达 BCMA 的 MM 细胞的选择性细胞毒性,平均半数有效浓度为 18.8 ± 14.8 pM。
- 皮下小鼠异种移植模型中所有测试剂量完全抑制肿瘤形成(P < .001)。
- 小鼠模型中抑制已建立肿瘤生长(P ≤ .001)并延长原位 MM 模型生存(P ≤ .01)。
- 食蟹猴中观察到剂量依赖性药代动力学和药效学行为,浆细胞特异性基因清除达血液 93%、骨髓 85%。
- 体外与 PD-1 阻断抗体联用显著增加 AMG 701 效力。
关键数值与推荐
- 体外平均半数有效浓度为 18.8 ± 14.8 pM。
- 食蟹猴浆细胞特异性基因清除:血液 93%,骨髓 85%。
- 数字 PCR assay 灵敏度为 0.1%。
临床怎么用
- AMG 701 可作为靶向 BCMA 的 BiTE 分子用于多发性骨髓瘤的临床开发。
- 与 PD-1 阻断抗体联用可能增强 AMG 701 的效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a hematologic malignancy that is characterized by the accumulation of abnormal plasma cells (PCs) in the bone marrow (BM). Patient outcome may be improved with BiTE (bispecific T-cell engager) molecules, which redirect T cells to lyse tumor cells. B-cell maturation antigen (BCMA) supports PC survival and is highly expressed on MM cells. A half-life extended anti-BCMA BiTE molecule (AMG 701) induced selective cytotoxicity against BCMA-expressing MM cells (average half-maximal effective concentration, 18.8 ± 14.8 pM), T-cell activation, and cytokine release in vitro. In a subcutaneous mouse xenograft model, at all doses tested, AMG 701 completely inhibited tumor formation (P < .001), as well as inhibited growth of established tumors (P ≤ .001) and extended survival in an orthotopic MM model (P ≤ .01). To evaluate AMG 701 bioactivity in cynomolgus monkeys, a PC surface phenotype and specific genes were defined to enable a quantitative digital droplet polymerase chain reaction assay (sensitivity, 0.1%). Dose-dependent pharmacokinetic and pharmacodynamic behavior was observed, with depletion of PC-specific genes reaching 93% in blood and 85% in BM. Combination with a programmed cell death protein 1 (PD-1)-blocking antibody significantly increased AMG 701 potency in vitro. A model of AMG 701 binding to BCMA and CD3 indicates that the distance between the T-cell and target cell membranes (ie, the immunological synapse) is similar to that of the major histocompatibility complex class I molecule binding to a T-cell receptor and suggests that the synapse would not be disrupted by the half-life extending Fc domain. These data support the clinical development of AMG 701.
引用
- Goldstein RL, Goyos A, Li CM, et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020. PMID: 32886754. doi:10.1182/bloodadvances.2020002565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。